GSK reports strong 2025 performance, reaffirms long-term outlook

GSK plc reported on February 4, 2026, a robust financial performance for the year 2025, with total sales rising 4% year-on-year to £32.7 billion. The company highlighted strong growth in its specialty medicines portfolio, which increased sales by 17% to £13.5 billion. This performance was driven by its respiratory, immunology, inflammation, oncology, and HIV segments.

The pharmaceutical giant also saw its vaccine sales reach £9.2 billion, marking a 2% increase. Key contributions came from products like Shingrix and Arexvy. GSK secured five major FDA approvals in 2025 and initiated several pivotal trials, while also strengthening its R&D pipeline through acquisitions and collaborations in oncology and immunology.

Total operating profit more than doubled, and total earnings per share also more than doubled, aided by lower legal expenses and higher other operating income, partially offset by impairments. The core operating profit grew by 11%, and core earnings per share by 12%, reflecting the strength in specialty medicines and vaccines, alongside SG&A productivity and disciplined R&D investments.

Looking ahead, GSK reaffirmed its 2026 guidance, expecting turnover growth of 3-5% and core operating profit growth of 7-9%. The company maintained its 2031 sales outlook of over £40 billion and continued its commitment to shareholder returns through dividends and share buybacks.